

specification as originally filed. Claim 25 has been rewritten as newly added claim 64 and claim 29 has been rewritten as newly added claim 65, in order to remove reference to non-elected species.

Claims 19, 20 and 22 have been amended to remove reference to cancelled claim 18 and add reference to newly added claim 61. Claim 22 has further been amended to recite a method for stimulating an immune response in a patient. Claims 26, 27 and 28 have been amended to remove reference to cancelled claim 25 and to add reference to newly added claim 64, and claim 30 has been amended to replace reference to cancelled claim 29 with reference to newly added claim 65. Claim 31 has been cancelled from the application.


It is urged that support for all the above amendments may be found throughout the specification as originally filed, and that none of these amendments constitute new matter. Furthermore, it is submitted that none of these amendments are being made for reasons related to patentability and therefore do not create prosecution history estoppel.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version with Markings to Show Changes Made.**"

Early consideration and allowance of the pending claims is respectfully requested.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jeffrey Hundley

Registration No. 42,676

JEH:dma

Enclosure:

Postcard

Check

Petition for an Extension of Time

701 Fifth Avenue, Suite 6300

Seattle, Washington 98104-7092

Phone: (206) 622-4900

Fax: (206) 682-6031

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 18, 25, 29 and 31 have been cancelled.

Claims 19, 20, 22, 26, 27, 28, and 30 have been amended, as follows:

19. (Amended) An immunogenic composition according to claim-18 61, wherein the immunostimulant is an adjuvant.

20. (Amended) An immunogenic composition according to claim-18 61, wherein the immunostimulant induces a predominantly Type I response.

22. (Amended) A method for ~~inhibiting the development of a cancer~~ stimulating an immune response in a patient, comprising administering to a patient an effective amount of an immunogenic composition according to claim-18 61.

26. (Amended) An immunogenic composition according to claim-25 64, wherein the immunostimulant is an adjuvant.

27. (Amended) An immunogenic composition according to claim-25 64, wherein the immunostimulant induces a predominantly Type I response.

28. (Amended) An immunogenic composition according to claim-25 64, wherein the antigen-presenting cell is a dendritic cell.

30. (Amended) A method according to claim-29 65, wherein the antigen-presenting cell is a dendritic cell.

New claims 61-65 have been added, as follows:

61. An immunogenic composition comprising an immunostimulant and a polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of:

- (a) SEQ ID NO: 113; and
- (b) immunogenic portions of SEQ ID NO: 113.

62. An immunogenic composition comprising an immunostimulant and a polypeptide, wherein the polypeptide comprises a sequence having at least 90% identity to SEQ ID NO: 113 and possesses an ability to stimulate a cytotoxic T lymphocyte response in sera from normal donors.

63. An immunogenic composition according to claim 61, wherein the immunostimulant is selected from the group consisting of: monophosphoryl lipid A; 3-de-O-acylated monophosphoryl lipid A; and saponins.

64. An immunogenic composition comprising an immunostimulant and an antigen-presenting cell that expresses a polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of:

- (a) SEQ ID NO: 113;
- (b) immunogenic portions of SEQ ID NO: 113; and
- (c) sequences having at least 90% identity to SEQ ID NO: 113, wherein the polypeptide possesses an ability to stimulate a cytotoxic T lymphocyte response in sera from normal donors.

65. A method for stimulating an immune response in a patient, comprising administering a composition according to claim 64.